Announcements Trials
Browse Landscape

Status

No longer available 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 870Observational 8Expanded_access 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

elotuzumab 4Bortezomib 4Lenalidomide 3Dexamethasone 3talquetamab 2selinexor 2pomalidomide 2carfilzomib 2Panobinostat 2venetoclax 1ulocuplumab 1plerixafor 1idecabtagene vicleucel 1fludarabine phosphate 1daratumumab 1ceritinib 1belantamab mafodotin 1Whole-Body Irradiation 1Tacrolimus 1Prednisone 1Mycophenolic Acid 1Melphalan 1Cytarabine 1Crizotinib 1Cord Blood Stem Cell Transplantation 1Calcium Dobesilate 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Expanded_access × Dexamethasone × Plasma cell × Clear all
NCT02856438 2023-12-19

Early Patient Access Treatment Use Protocol CA204-220

Bristol-Myers Squibb

No longer available
Plasma cell

Multiple Myeloma

NCT02368301 2023-11-30

Expanded Access Treatment Protocol CA204-143

Bristol-Myers Squibb

No longer available
Plasma cell

Multiple Myeloma

NCT02666209 2017-08-28

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Dana-Farber Cancer Institute

No longer available
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡